The Indianapolis facility would serve as Exo-Top’s U.S. manufacturing base, transferring NurExone’s proprietary exosome production process into the American market. The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.

“Indiana’s commitment to building its life sciences cluster, outstanding logistics and strong incentives offer make Indianapolis the ideal home for Exo-Top, and we are honored to consider expanding into Indiana with the support of the Indiana Office of Commerce,” said Jacob Licht, CEO of Exo-Top. “By joining this ecosystem, we would contribute to Indiana’s biomanufacturing growth while securing a U.S. foundation for our therapeutic and commercial programs.”

READ MORE >>>

The post NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana appeared first on NurExone.

The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently announced U.S. Notice of Allowance for the same priority family of applications.

“While our clinical and commercial manufacturing of exosomes will be based in the U.S. through our Exo-Top Inc. subsidiary, expanding jurisdictional coverage further strengthens NurExone’s international intellectual property portfolio,” said Dr. Lior Shaltiel, CEO of NurExone.

Read More >>>

The post NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing appeared first on NurExone.

“This U.S. patent allowance secures long-term protection for our proprietary manufacturing process,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “With patent coverage in place and the recent acquisition of a Good Manufacturing Practice (“GMP”)-grade Master Cell Bank, we have reinforced the core elements of our supply chain. Combined with independent benchmarking that demonstrated the stronger regenerative potential of our exosomes, this milestone strengthens our path towards first-in-human trials and future commercial positioning.”

Prof. Shulamit Levenberg, lead inventor and NurExone Scientific Advisor, added: “This technology, which originated in my lab at the Technion, represents a unique and scalable method of manufacturing stem-cell derived exosomes. The allowance of this patent validates years of research and ensures that NurExone retains lasting intellectual property as it advances into clinical and commercial phases.”

READ MORE >>>

The post NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness appeared first on NurExone.

The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2025, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.

Read More >>>

The post NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results appeared first on NurExone.

An imaging-based analysis of animals treated with ExoPTEN after a spinal cord injury showed more organized spinal cord tissue compared to untreated controls. A functional assessment of this same cohort showing that 100% of animals in a higher-dose group regained motor function was published in July 2025.

“The data from the MRI with Diffusion Tensor Imaging (“MRI-DTI”) indicates that the injured spinal cords showed greater structural integrity and tissue organization when treated with ExoPTEN in the animal model. Importantly, those structurally preserved spinal cords strengthen the accumulating evidence of ExoPTEN neuroprotective and regeneration-promoting activity following spinal cord injury,” said Dr. Kineret Taler, Head of Preclinical Studies.

READ MORE >>>

The post NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment appeared first on NurExone.

Read More >>>

The post Architects of Tomorrow’s Regenerative Medicine Breakthroughs appeared first on NurExone.

“This data confirms that the naïve exosomes that will be manufactured by our U.S. subsidiary, ExoTOP Inc. (“ExoTOP”), will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care and orthopedic tissue repair”, said Jacob Licht, Chief Executive Officer of ExoTOP. “As we scale production in the United States with our patent-pending 3D production process, ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine.”

READ MORE >>>

The post NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard appeared first on NurExone.